NO975369L - Fremgangsmåter for å inhibere glattmuskelcellemigrering - Google Patents

Fremgangsmåter for å inhibere glattmuskelcellemigrering

Info

Publication number
NO975369L
NO975369L NO975369A NO975369A NO975369L NO 975369 L NO975369 L NO 975369L NO 975369 A NO975369 A NO 975369A NO 975369 A NO975369 A NO 975369A NO 975369 L NO975369 L NO 975369L
Authority
NO
Norway
Prior art keywords
methods
smooth muscle
cell migration
muscle cell
inhibit smooth
Prior art date
Application number
NO975369A
Other languages
English (en)
Norwegian (no)
Other versions
NO975369D0 (no
Inventor
Jai Pal Singh
Todd R Wiernicki
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975369D0 publication Critical patent/NO975369D0/no
Publication of NO975369L publication Critical patent/NO975369L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO975369A 1995-06-01 1997-11-21 Fremgangsmåter for å inhibere glattmuskelcellemigrering NO975369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/457,700 US5622975A (en) 1995-06-01 1995-06-01 Methods for inhibiting vascular smooth muscle cell migration
PCT/US1996/008037 WO1996038145A1 (en) 1995-06-01 1996-05-30 Methods for inhibiting vascular smooth muscle cell migration

Publications (2)

Publication Number Publication Date
NO975369D0 NO975369D0 (no) 1997-11-21
NO975369L true NO975369L (no) 1997-11-21

Family

ID=23817780

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975369A NO975369L (no) 1995-06-01 1997-11-21 Fremgangsmåter for å inhibere glattmuskelcellemigrering

Country Status (20)

Country Link
US (1) US5622975A (cs)
EP (1) EP0745384A3 (cs)
JP (1) JPH11509836A (cs)
KR (1) KR19990022053A (cs)
CN (1) CN1089237C (cs)
AU (1) AU707756B2 (cs)
CA (1) CA2222292A1 (cs)
CZ (1) CZ287958B6 (cs)
EA (1) EA000190B1 (cs)
HU (1) HUP9900851A3 (cs)
IL (1) IL118483A (cs)
MY (1) MY112973A (cs)
NO (1) NO975369L (cs)
NZ (1) NZ309390A (cs)
PL (1) PL323786A1 (cs)
RO (1) RO117996B1 (cs)
UA (1) UA42835C2 (cs)
WO (1) WO1996038145A1 (cs)
YU (1) YU32196A (cs)
ZA (1) ZA964439B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6124260A (en) 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
IL112034A (en) * 1993-12-21 1999-03-12 Lilly Co Eli Use of raloxifene and related compounds in the preparation of medicaments useful for the inhibition of ldl oxidation and atherosclerosis

Also Published As

Publication number Publication date
HUP9900851A2 (hu) 1999-09-28
EP0745384A3 (en) 1997-02-26
PL323786A1 (en) 1998-04-27
US5622975A (en) 1997-04-22
HUP9900851A3 (en) 1999-11-29
RO117996B1 (ro) 2002-12-30
CN1191487A (zh) 1998-08-26
NZ309390A (en) 2000-07-28
EA199700450A1 (ru) 1998-06-25
CZ374497A3 (cs) 1998-06-17
WO1996038145A1 (en) 1996-12-05
AU5954196A (en) 1996-12-18
UA42835C2 (uk) 2001-11-15
MX9709189A (es) 1998-03-31
CZ287958B6 (cs) 2001-03-14
IL118483A (en) 2000-06-29
NO975369D0 (no) 1997-11-21
IL118483A0 (en) 1996-09-12
CN1089237C (zh) 2002-08-21
MY112973A (en) 2001-10-31
YU32196A (sh) 1999-06-15
CA2222292A1 (en) 1996-12-05
AU707756B2 (en) 1999-07-22
KR19990022053A (ko) 1999-03-25
JPH11509836A (ja) 1999-08-31
ZA964439B (en) 1997-12-01
EA000190B1 (ru) 1998-12-24
EP0745384A2 (en) 1996-12-04

Similar Documents

Publication Publication Date Title
NO975369L (no) Fremgangsmåter for å inhibere glattmuskelcellemigrering
EP0745843A3 (en) Electrochemical immunobiosensor
DE59605850D1 (de) Lithium-ionen-zelle
ATE201709T1 (de) Bituminöse zusammensetzung
DE69634735D1 (de) Brennstoffzelle
FI960660L (fi) Parannuksia platinakomplekseihin
EP0888067A4 (en) Chewable compositions
NO992925L (no) Fremgangsmåte for å öke produksjon av sjömat i ufruktbart hav
IT1284656B1 (it) Cella elettrolitica
DE69620940D1 (de) Bituminöse Zusammensetzung
FI971936L (fi) Sileän lihaskudoksen solujen lisääntymisen estäjät
DE69606884D1 (de) Schichtladungsbrennkraftmaschine
FI972968A7 (fi) Menetelmiä kasvuhormonivaikutusten estämiseksi
NO973963D0 (no) Fremgangsmåte for å hemme ovariecancer
KR960035933U (ko) 비닐하우스용 재생가능 보온 덮개
FI954892A0 (fi) Telarakenne
FI952676A0 (fi) Kerrosrakenne
KR960035948U (ko) 집란장치
KR970006177A (ko) 증류수기
KR960035904U (ko) 비닐 수거기
KR970025762U (ko) Pcm 고정 구조
KR960026440U (ko) 전지용 톱
KR970026525U (ko) 비닐하우스용 철골 아취구조
KR970017908U (ko) 좋은 물 창조기
KR970042039U (ko) 탈거가 용이한 패스너

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application